Compare TIPT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIPT | VOR |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.8M | 755.7M |
| IPO Year | 2017 | 2021 |
| Metric | TIPT | VOR |
|---|---|---|
| Price | $17.21 | $14.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 208.3K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $488,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.49 | $0.13 |
| 52 Week High | $27.38 | $49.95 |
| Indicator | TIPT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 48.75 |
| Support Level | $17.15 | $11.38 |
| Resistance Level | $18.15 | $16.88 |
| Average True Range (ATR) | 0.32 | 1.57 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 81.12 | 21.95 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.